Status:

UNKNOWN

Impact of Acute and Chronic Inflammation on Cytochromes P450 Activity Measured With Dried Blood Spot

Lead Sponsor:

University Hospital, Geneva

Conditions:

Inflammation

Eligibility:

All Genders

18+ years

Brief Summary

Cytochromes P450, main enzymes of drug metabolism, play a prominent role in the first-pass metabolism of oral substances. Inter-individual variability in their activity due to genetic and environmenta...

Eligibility Criteria

Inclusion

  • -\> For hip surgery and chronic inflammation groups
  • Male and female patients diagnosed with rheumatoid arthritis or undergoing an elective hip surgery
  • Age \> 18 years old
  • Understanding of French language and ability to give a written inform consent
  • For SARS-CoV-2 infection group
  • Male and female patients diagnosed with SARS-CoV-2 infection (positive RT-PCR) and CRP \> 30 mg/L
  • Age \> 18 years old
  • Understanding of French language and ability to give a written inform consent
  • -\>

Exclusion

  • For hip surgery and chronic inflammation groups
  • Pregnant or lactating females
  • Severe cardiac failure, severe edema or ascites
  • Severe COPD or pulmonary embolism requiring oxygen
  • Uncontrolled infection
  • Active cancer
  • HIV infection
  • Renal impairment (defined as serum creatinine concentrations \> 1.5 x ULN)
  • Hepatic impairment (alteration of hepatic tests AST, ALT, bilirubin, GGT \>2 x ULN)
  • Inability to give blood samples
  • Sensitivity to any of the drugs used
  • Intake of drugs altering CYPs activity (based on \[1\]) except for tocilizumab
  • For SARS-CoV-2 infection group
  • Pregnant or lactating females
  • Hospitalized in intensive care unit at time of inclusion
  • Hospitalized in intermediate care unit at time of inclusion
  • Active cancer
  • HIV infection
  • Renal impairment (glomerular filtration rate \< 30 mL/min/1.73m2)
  • Hepatic impairment (Child-Pugh score B and C)
  • Inability to give blood samples
  • Sensitivity to any of the drugs used

Key Trial Info

Start Date :

September 1 2017

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2021

Estimated Enrollment :

106 Patients enrolled

Trial Details

Trial ID

NCT03262051

Start Date

September 1 2017

End Date

September 1 2021

Last Update

March 4 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Geneva University Hospitals, HUG

Geneva, Switzerland